Treatment of high-risk neuroblastoma in children: recent clinic trial results
Clinical Investigation · 2013-11 · 3 (11) · 1071-1081
DOI: 10.4155/cli.13.90 ↗At a glance
Journal article in Clinical Investigation, 2013-11. Written by Emily Greengard and 2 co-authors. Cited 5 times so far (Crossref); 84 references.
Topics: Kinderkrankenpflege
Abstract (original language)
Neuroblastoma is the most common extracranial solid tumor in childhood and accounts for 15% of all pediatric oncology deaths. Children with high-risk disease have a particularly poor prognosis, with nearly half succumbing to their disease despite aggressive multimodal therapy. A better understanding of the biological and clinical risk factors over the past few decades have led to significant breakthroughs and a series of clinical trials have improved outcomes for children with high-risk neuroblastoma. Despite this, many children will still die of their disease and novel approaches are desperately needed. The purpose of this review is to summarize the outcomes of recent clinical trials for children with high-risk neuroblastoma.
Cite
APA
Greengard, E., Hill-Kayser, C., & Bagatell, R. (2013). Treatment of high-risk neuroblastoma in children: recent clinic trial results. Clinical Investigation, 3(11), 1071-1081. https://doi.org/10.4155/cli.13.90
Vancouver
Greengard E, Hill-Kayser C, Bagatell R. Treatment of high-risk neuroblastoma in children: recent clinic trial results. Clinical Investigation. 2013;3(11):1071-1081. doi:10.4155/cli.13.90
BibTeX
@article{Greengard2013,
author = {Greengard, Emily and Hill-Kayser, Christine and Bagatell, Rochelle},
title = {Treatment of high-risk neuroblastoma in children: recent clinic trial results},
journal = {Clinical Investigation},
year = {2013},
volume = {3},
number = {11},
pages = {1071--1081},
doi = {10.4155/cli.13.90}
}
EUVIMED